Needham & Company Reiterates Autolus Therapeutics plc (AUTL) at Buy, Views Clinical Profile of obe-cel as Potentially Best-in-Class
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $13.00 price target on Autolus Therapeutics plc (NASDAQ: AUTL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
